Product Information
TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) is a generic product labeled by Glenmark Pharmaceuticals Inc., USA, priced at $0.6881 per EA under NDC 68462068701. Its NADAC has been published 269 times since Aug 11, 2021.
FDA first approved this application on Nov 10, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Glenmark Pharmaceuticals Inc., USANDC
68462068701
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TACROLIMUSApproval Type
Generic (ANDA)
FDA Application
ANDA206662FDA Approved
11/10/2020
TE Code
AB
On Market Since
11/10/2020
Pharmacological Classes
Price Statistics
The NADAC for TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) has been published 269 times since Aug 11, 2021, and over the history we have for it it has declined 51.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6881 per EA |
|---|---|
| All-time high | $2.4642 (Sep 14, 2022) |
| All-time low | $0.6505 (Jun 17, 2026) |
| 52-week high | $0.8265 |
| 52-week low | $0.6505 |
| Median price | $1.1227 |
| Average price | $1.2558 |
| Largest weekly change | -39.2% (Sep 21, 2022) |
| Weeks tracked | 269 |
| Tracking since | Aug 11, 2021 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Glenmark Pharmaceuticals Inc., USA manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
tacrolimus market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcineurin Inhibitor Immunosuppressant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE)?
The current National Average Drug Acquisition Cost (NADAC) for TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE), manufactured by Glenmark Pharmaceuticals Inc., USA, is $0.6881 per EA (NDC 68462068701), effective Sep 30, 2026.
How has the price of TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) changed over time?
Over the history we have for it, the NADAC for TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) has declined 51.5%. It has been tracked across 269 weekly CMS publications since Aug 11, 2021.
What are the highest and lowest recorded NADAC prices for TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE)?
Since Aug 11, 2021, the NADAC for TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) has ranged from a low of $0.6505 (Jun 17, 2026) to a high of $2.4642 (Sep 14, 2022), with a median of $1.1227 per EA.
Are there cheaper alternatives to TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE)?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) in a comparable dosage form, but none are currently priced below it.
Who manufactures TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE)?
TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) (NDC 68462068701) is labeled by Glenmark Pharmaceuticals Inc., USA, and CMS classifies it as a generic product.